Literature DB >> 2971501

Antimicrobial agent resistance in Neisseria gonorrhoeae in St. Paul Minnesota.

R T Lally1, B F Woolfrey, M E Gresser-Burns, K Henry.   

Abstract

In a prospective survey of 283 Neisseria gonorrhoeae isolated in St. Paul, Minnesota, 5% were found to produce beta-lactamase, and 11% were resistant to penicillin by chromosomal mediation, thus indicating a hyperendemic level of resistance according to Centers for Disease Control guidelines. A significant level of chromosomal resistance (30%) was noted for tetracycline, and MICs for spectinomycin approached the upper limits of susceptibility for a large number of isolates. The need for uniformity in agar dilution test methodology is discussed, and the variability in antimicrobial agent interpretive breakpoint criteria is illustrated by comparing penicillin breakpoints published by the Centers for Disease Control with those of the National Committee for Clinical Laboratory Standards as applied to the study isolates.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971501     DOI: 10.1016/0732-8893(88)90126-5

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

1.  Survey of Neisseria gonorrhoeae antimicrobial susceptibility in Ontario.

Authors:  V G Loo; A E Simor; R Jaeger; D E Low
Journal:  Can J Infect Dis       Date:  1990

2.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

Review 3.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.

Authors:  T Fekete
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.